Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer.

摘要

Given the remarkable early successes of vaccine effectiveness in reduction of HPV-vaccine-related infections in vaccine-eligible age females, rapid reduction in genital warts (first marker of disease reduction and herd immunity) and high-grade cervical lesions, in countries where vaccine has high coverage of target populations, vaccination should ultimately translate into reductions in HPV-related neoplasias. The greatest success from this vaccine will only be realized when it is rolled out effectively, with high coverage to those parts in the world with the highest burden of disease. We have the tools; we now need to use them.